Jaume Pons, Ph.D., Scientific Advisor

Dr. Pons currently serves as the President and Chief Executive Officer of ALX Oncology. He previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron.


Ph.D. in Molecular and Cell Biology from the Institute on Fundamental Biology, Barcelona
M.S. in Biotechnology from Autonoma University of Barcelona
B.S. in Biochemistry from Autonoma University of Barcelona
Postdoctoral studies in Antibody Engineering from the University of California, Berkeley

Sector: Biopharmaceuticals

Location: Menlo Park

See other team members.